Daniel Benjamin Mark, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8775
Email address mark0004@mc.duke.edu

Dr. Mark is a clinical cardiologist with the rank of Professor of Medicine (with tenure) as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. He has been on the full-time faculty at Duke since 1985. Prior to that he completed his cardiology fellowship at Duke, his residency and internship at the University of Virginia Hospital, and received his medical degree from Tufts University and his Master’s degree from Harvard. In 1998, he was given the honor of being elected to the American Society for Clinical Investigators and in 2002 he was honored by election to the Association of American Physicians. These organizations are the two most prestigious honor societies in academic medicine. In 2009, Dr. Mark was awarded the American College of Cardiology Distinguished Scientist Award.

Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing clinical trials including PROMISE (anatomic versus functional testing for coronary artery disease, NIH), CABANA (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation, NIH), ISCHEMIA (percutaneous coronary intervention versus optimal medical therapy for moderate-severe ischemia), and STICH (CABG +/- ventricular reconstruction versus medical therapy for ischemic heart disease, NIH). He was the principal author of the AHCPR Unstable Angina Guidelines and is a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline. He is also the Editor of the American Heart Journal. Dr. Mark has published over 270 peer-reviewed articles, two books, and 80 book chapters. He lectures widely in the US, as well as in Canada, South America, and Europe.

Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Education and Training

  • M.D., Tufts University, 1978

Publications

Mark, DB, Richman, I, and Hlatky, MA. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy-Breakthrough in Low-Density Lipoprotein Cholesterol Lowering, Breakdown in Value." JAMA cardiology (August 23, 2017).

PMID
28832860
Full Text

Hess, PL, Al-Khalidi, HR, Friedman, DJ, Mulder, H, Kucharska-Newton, A, Rosamond, WR, Lopes, RD, Gersh, BJ, Mark, DB, Curtis, LH, Post, WS, Prineas, RJ, Sotoodehnia, N, and Al-Khatib, SM. "The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study." Journal of the American Heart Association 6, no. 8 (August 23, 2017).

PMID
28835363
Full Text

Califf, RM, McCall, J, and Mark, DB. "Cosmetics, Regulations, and the Public Health: Understanding the Safety of Medical and Other Products." Jama Internal Medicine 177, no. 8 (August 2017): 1080-1082.

PMID
28655035
Full Text

Felker, GM, Anstrom, KJ, Adams, KF, Ezekowitz, JA, Fiuzat, M, Houston-Miller, N, Januzzi, JL, Mark, DB, Piña, IL, Passmore, G, Whellan, DJ, Yang, H, Cooper, LS, Leifer, ES, Desvigne-Nickens, P, and O'Connor, CM. "Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial." Jama 318, no. 8 (August 2017): 713-720.

PMID
28829876
Full Text

Mark, DB, and Schulman, KA. "PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability." JAMA 318, no. 8 (August 2017): 711-712.

PMID
28829851
Full Text

Guimarães, PO, Krishnamoorthy, A, Kaltenbach, LA, Anstrom, KJ, Effron, MB, Mark, DB, McCollam, PL, Davidson-Ray, L, Peterson, ED, and Wang, TY. "Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study." Jama Cardiology 2, no. 7 (July 2017): 750-757.

PMID
28538984
Full Text

Rogers, JG, Patel, CB, Mentz, RJ, Granger, BB, Steinhauser, KE, Fiuzat, M, Adams, PA, Speck, A, Johnson, KS, Krishnamoorthy, A, Yang, H, Anstrom, KJ, Dodson, GC, Taylor, DH, Kirchner, JL, Mark, DB, O'Connor, CM, and Tulsky, JA. "Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial." Journal of the American College of Cardiology 70, no. 3 (July 2017): 331-341.

PMID
28705314
Full Text

Al-Khatib, SM, Fonarow, GC, Joglar, JA, Inoue, LYT, Mark, DB, Lee, KL, Kadish, A, Bardy, G, and Sanders, GD. "Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis." Jama Cardiology 2, no. 6 (June 2017): 685-688.

PMID
28355432
Full Text

Hoffmann, U, Ferencik, M, Udelson, JE, Picard, MH, Truong, QA, Patel, MR, Huang, M, Pencina, M, Mark, DB, Heitner, JF, Fordyce, CB, Pellikka, PA, Tardif, J-C, Budoff, M, Nahhas, G, Chow, B, Kosinski, AS, Lee, KL, Douglas, PS, and PROMISE Investigators, . "Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain)." Circulation 135, no. 24 (June 2017): 2320-2332.

PMID
28389572
Full Text

Mark, DB, Hansen, SM, Starks, ML, and Cummings, ML. "Drone-Based Automatic External Defibrillators for Sudden Death? Do We Need More Courage or More Serenity?." Circulation 135, no. 25 (June 2017): 2466-2469.

PMID
28630265
Full Text

Pages